NPI: 1679529267 · MEMPHIS, TN 38104 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 05/25/2006
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 05/25/2006 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 30,637 | $368K |
| 2019 | 26,614 | $294K |
| 2020 | 21,591 | $248K |
| 2021 | 15,401 | $156K |
| 2022 | 11,865 | $156K |
| 2023 | 2,758 | $75K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 38,035 | 2,637 | $1.23M |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 29,662 | 1,659 | $60K |
| J0604 | Cinacalcet, oral, 1 mg, (for esrd on dialysis) | 2,621 | 791 | $4K |
| J1270 | Injection, doxercalciferol, 1 mcg | 18,830 | 1,507 | $1K |
| J1756 | Injection, iron sucrose, 1 mg | 5,945 | 1,464 | $885.75 |
| 90674 | 59 | 58 | $25.94 | |
| G0008 | Administration of influenza virus vaccine | 149 | 129 | $3.38 |
| 83550 | 1,602 | 1,514 | $0.00 | |
| A4657 | Syringe, with or without needle, each | 3,375 | 1,934 | $0.00 |
| 82728 | 1,012 | 951 | $0.00 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 323 | 224 | $0.00 |
| 85048 | 1,642 | 1,511 | $0.00 | |
| 83540 | 1,829 | 1,707 | $0.00 | |
| 85041 | 1,648 | 1,507 | $0.00 | |
| 82108 | 144 | 134 | $0.00 | |
| 83970 | 1,937 | 1,587 | $0.00 | |
| 90662 | 53 | 50 | $0.00 |